FORMAC Pharmaceuticals

FlandersBio on Twitter

arGEN-X advances a third therapeutic antibody program into preclinical development: http://t.co/hBB8aUOQ

posted 2 days ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.formacpharma.com
Email:
Phone: +32 16 751 370
FlandersBio Member
More address details

Business Focus

Formac Pharmaceuticals has developed three proprietary drug delivery technologies allowing pharmaceutical companies to rescue poorly soluble bioactive drug candidates and redirect their development towards value medicines. The FORMAC solubilization technologies can also be applied for line extension development of clinical drug candidates or established marketed drugs.

Company Profile

FORMAC is a pharmaceutical R&D company engaged in drug delivery and development. Our mission is to increase pharmaceutical R&D productivity and product value by enhancing the performance of (pre)clinical drug candidates and marketed drugs.

FORMAC has developed a unique oral drug delivery technology platform, including three technologies to enhance the bioavailability of poorly soluble compounds and one technology to develop tailor-made controlled release formulations.

FORMAC uses its proprietary drug delivery technologies as a starting-point for the development and commercialization of improved delivery forms of marketed drugs. In addition, FORMAC licenses its technology platform to pharmaceutical companies for formulation development of pre-clinical drug candidates and for the development of line extensions of advanced clinical drug candidates (life cycle management).

FORMAC is a privately held company established in 2007 as a spin-off project from the University of Leuven (K.U.Leuven).

Science & Technology or Services

FORMAC is a technology-based company applying a product-focused strategy with the objective to build over the next few years a balanced product-portfolio in one or two disease areas.

In order to fully exploit its unique technology platform, FORMAC applies a dual business approach using the proceeds generated by contract R&D activities to accelerate and expand its internal development programs, which eventually will be partnered with pharmaceutical and generic drug companies. This strategy will allow us to progressively increase value for our shareholders, employees, corporate partners and patients.